A client with breast cancer is starting doxorubicin chemothe… | MyMerci
Medical EmergenciesPA
Question
A client with breast cancer is starting doxorubicin chemotherapy. Which baseline assessment is essential before the first dose?
1Baseline echocardiogram or MUGA scan for LVEF — doxorubicin causes dose-dependent cumulative cardiotoxicity✓ Correct answer
2Bone density scan
3Pulmonary function test
4Cervical cancer screening
Explanation
Correct (2): Doxorubicin (and other anthracyclines) cause dose-dependent cumulative cardiomyopathy; lifetime dose ≤450-550 mg/m². Baseline LVEF via echo or MUGA + periodic monitoring. Dexrazoxane is a cardioprotectant in high-dose regimens. Also expect red urine (harmless) and severe vesicant risk. (1,3,4) Unrelated to anthracycline cardiac safety.
In-depth explanation
Memory Tip Anthracycline = "Red Devil" — red urine, red drug, red flag for HEART. Dexrazoxane = cardioprotectant. Lifetime dose cap critical.
Clinical scenario
Scenario 52-year-old female with stage III breast cancer starting doxorubicin regimen. Pre-treatment workup.